The Australian Diabetes, Obesity and Lifestyle Study - Profiling Diabetes and Cardiovascular Disease Risk in the Nation

Login or register to view PDF.
Asia Pacific Cardiology - Volume 2 Issue 1;2008:2(1):25-28


The Australian Diabetes, Obesity and Lifestyle (AusDiab) study is an ongoing national, longitudinal, population-based study designed to examine the prevalence, natural history and risk factors of diabetes, pre-diabetes, heart disease and renal disease in Australia. The AusDiab study is one of the few national diabetes surveys to use an oral glucose tolerance test (OGTT), and the only study of its kind in the developed world. Therefore, it is an important resource not only to Australia but also to the rest of the world.
The AusDiab study resulted from observations of a global pattern suggestive of an emerging diabetes epidemic, about which little was known in Australia. The project began with a baseline study of 11,247 Australians conducted throughout 1999 and 2000 that provided benchmark national data on the prevalence of diabetes, obesity, hypertension and kidney disease. The second phase of the AusDiab study, completed in December 2005, was a five-year follow-up of the cohort established in 2000 and provided a unique picture of the incidence of diabetes, cardiovascular disease and kidney disease over five years. The planned 10-year follow-up of the AusDiab cohort will also involve a new prevalence survey in order to track changes in the magnitude of the diabetes epidemic in Australia.

Local Needs for Data and a National Survey

The AusDiab study was the first national Australian study to measure the prevalence of diabetes using an OGTT. Previous estimates of diabetes prevalence in Australia came from regular self-reported National Health Surveys,1 a National Heart Foundation survey in 1983 that measured fasting blood glucose but was conducted only in large cities,2 and two studies that used an OGTT – one in the rural Western Australian town of Busselton in 19813 and the other a small study from rural Victoria.4 The national prevalence of undiagnosed diabetes, as well as the pre-diabetic states of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), could only be guessed at when the first AusDiab study was conducted. It had been over a decade since any national blood survey had been conducted in Australia to allow estimation of the prevalence of dyslipidaemia. The impetus for a national diabetes study increased with the decision by Australian health ministers in 1996 to include diabetes as one of six national health priority areas, the signing by the health ministers in 1999 of the Australian Diabetes Declaration and the endorsement of the National Diabetes Strategy 2000–2004. Politicians, health planners and researchers had all recognised the need for accurate diabetes data and the AusDiab study was established in order to fill this need.


  1. Australia National Health Survey, Summary of results, Canberra: Australian Bureau of Statistics, 1997.
  2. National Heart Foundation of Australia, Risk Factor Prevalence Study No. 2. Canberra: National Heart Foundation, 1983.
  3. Glatthaar C, Welborn TA, Stenhouse NS, Garcia-Webb P, Diabetes and impaired glucose tolerance. A prevalence estimate based on the Busselton 1981 survey, Med J Australia, 1985;143:436–40.
  4. Guest C, O’Dea K, Hopper J, et al., The prevalence of glucose intolerance in Aborigines and Europids of south-east Australia, Diab Res Clin Pract, 1992;15:227–35.
  5. World Health Organization, Diabetes and Non-communicable Disease Risk Factor Surveys – A Field Guide. Geneva: World Health Organization, 1999.
  6. Dunstan DW, Zimmet PZ, Welborn TA, et al., The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study, Diabetes Care, 2002;25:829–34.
  7. Cameron AJ, Welborn TA, Zimmet PZ, et al., Overweight and obesity in Australia: the 1999–2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab), Med J Australia, 2003;178:427–32.
  8. Australian Institute of Health and Welfare (AIHW), The Active Australia Survey. A guide and manual for implementation, analysis and reporting,, 2003.
  9. Dunstan DW, Salmon J, Owen N, et al., Physical activity and television viewing in relation to risk of undiagnosed abnormal glucose metabolism in adults, Diabetes Care, 2004;27:2603–9.
  10. Dunstan DW, Salmon J, Healy GN, et al., Association of television viewing with fasting and 2-h post-challenge plasma glucose levels in adults without diagnosed diabetes, Diabetes Care, 2007;30:516–22.
  11. Dwyer T, Hosmer D, Hosmer T, et al., The inverse relationship between number of steps per day and obesity in a population-based sample: the AusDiab study, Int J Obesity, 2005;31:797–804.
  12. Healy GN, Dunstan DW, Salmon J, et al., Objectively measured light-intensity physical activity is independently associated with 2-h plasma glucose, Diabetes Care, 2007;30:1384–9.
  13. Tapp RJ, Shaw JE, Harper CA, et al., The prevalence of and factors associated with diabetic retinopathy in the Australian population, Diabetes Care, 2003;26:1731–7.
  14. Atkins RC, Briganti EM, Zimmet PZ, Chadban SJ, Association between albuminuria and proteinuria in the general population: the AusDiab Study, Nephrol Dial Transplant, 2003;18:2170–74.
  15. Chadban SJ, Briganti EM, Kerr PG, et al., Prevalence of kidney damage in Australian adults: The AusDiab kidney study, J Am Soc Nephrol, 2003;14:S131–8.
  16. Tapp RJ, Shaw JE, de Courten MP, et al., Foot complications in Type 2 diabetes: an Australian population-based study, Diabet Med, 2003;20:105–13.
  17. Tapp RJ, Zimmet PZ, Harper CA, et al., Diabetes care in an Australian population: frequency of screening examinations for eye and foot complications of diabetes, Diabetes Care, 2004;27:688–93.
  18. UK Prospective Diabetes Study Group, Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 1998;352:837–53.
  19. UKPDS, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group, Bmj, 1998;317:703–13.
  20. Collins R, Armitage J, Parish S, et al., MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial, Lancet, 2003;361:2005–16.
  21. Hansson L, Zanchetti A, Carruthers SG, et al., Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group, Lancet, 1998;351:1755–62.
  22. National Heart Foundation and Australian Institute of Health. Risk Factor Prevalence Study No. 3 1989, Canberra: National Heart Foundation and Australian Institute of Health, 1990.
  23. Best JD, Jerums G, Newnham HH, O’Brien RC, Diabetic dyslipidaemia. Australian Diabetes Society position statement, Med J Australia, 1995;162:91–3.
  24. Diabetes Australia and Royal Australian College of General Practice (RACGP). Diabetes management in general practice, 5th edition. Canberra: Diabetes Australia, 1998.
  25. Dyslipidemia management in adults with diabetes (Technical Review), Diabetes Care, 2004;27(Suppl. 1):S68–71.
  26. Hypertension management in adults with diabetes (Technical Review), Diabetes Care, 2004;27(Suppl. 1):S65–7.
  27. Standards of medical care in diabetes, Diabetes Care, 2004;27(Suppl. 1):S15–35.
  28. Kemp TM, Barr EL, Zimmet PZ, et al., Glucose, lipid and blood pressure control in Australian adults with type 2 diabetes: the 1999–2000 AusDiab, Diabetes Care, 2005;28:1490–92.
  29. Barr L, Magliano D, Zimmet P, et al., AusDiab 2005. The Australian Diabetes, Obesity and Lifestyle Study. Tracking the Accelerating Epidemic: Its Causes and Outcomes. Melbourne: International Diabetes Institute, 2006.
  30. Barr EL, Zimmet PZ, Welborn TA, et al., Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab), Circulation, 2007;116:151–7.
  31. Dunstan DW, Zimmet PZ, Welborn TA, et al., The Australian Diabetes, Obesity and Lifestyle Study (AusDiab) – methods and response rates, Diabetes Res Clin Pr, 2002;57:119–29.
  32. Simmons D, McKenzie A, Eaton S, et al., Prevalence of diabetes in rural Victoria, Diabetes Res Clin Pr, 2005;70:287–90.